Physician profile
David B Sable
NPI 1245216092
$4,732.71
in general payments reported to CMS, 2019-2025
29 companies · $2,478 in 2025
The $2,478 reported for 2025 was more than what 81% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $376 · 2020: $123 · 2021: $258 · 2022: $272 · 2023: $596 · 2024: $630 · 2025: $2,478.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,000 · Food and Beverage: $1,696 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,000.00 |
| Food and Beverage | $1,695.51 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $2,159.79 | 2019-2025 | Blu-U, Odomzo |
| Abbvie INC. | $771.31 | 2021-2025 | Rinvoq, Skyrizi |
| Leo Pharma INC. | $234.18 | 2019-2023 | Adbry |
| Novartis Pharmaceuticals Corporation | $210.05 | 2019-2025 | |
| Amgen INC. | $179.31 | 2021-2025 | Otezla, Otezla |
| Regeneron Healthcare Solutions, INC. | $171.83 | 2019-2025 | Libtayo, Dupixent |
| Genzyme Corporation | $142.22 | 2019-2025 | |
| Pfizer INC. | $128.88 | 2019-2025 | |
| Lilly USA, LLC | $119.15 | 2019-2024 | Taltz, Olumiant, Ebglyss |
| Organogenesis INC. | $90.17 | 2021-2025 | Novachor, Affinity |
| Celgene Corporation | $48.96 | 2019 | |
| Galderma Laboratories, L.P. | $45.74 | 2019-2025 | Nemluvio, Aklief |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $44.96 | 2019-2021 | |
| Sebela Pharmaceuticals INC. | $40.59 | 2021-2023 | Naftin |
| Janssen Biotech, INC. | $36.47 | 2019-2024 | Tremfya |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kerecis Limited | $31.05 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Incyte Corporation | $29.66 | 2023 | Opzelura |
| Arcutis Biotherapeutics, INC. | $29.26 | 2023-2024 | Zoryve |
| Dermavant Sciences, INC. | $25.01 | 2024 | Vtama |
| Genentech USA, INC. | $24.60 | 2023 | Xolair |
| Verrica Pharmaceuticals INC. | $24.36 | 2024 | Ycanth |
| Smith+Nephew, INC. | $23.34 | 2022 | |
| Allergan, INC. | $20.87 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.10 | 2022 | |
| Cipher Pharmaceuticals US LLC | $19.55 | 2025 | Natroba, Spinosad |
| Almirall LLC | $19.26 | 2024 | Seysara |
| Convatec INC. | $15.43 | 2023 | |
| Dermira, INC. | $14.48 | 2021 | |
| Strata Skin Sciences, INC. | $12.13 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Sable listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.